What is a partial agonist in simple terms?

A receptor ligand that can only push the receptor part of the way to its maximum response, even at very high doses. The ceiling on its response is a property of the ligand itself.

What is the difference between a partial agonist and a full agonist?

A full agonist can produce the maximum functional response the receptor system is capable of (Emax = 100% relative to reference). A partial agonist produces a submaximal Emax even at saturating concentration.

What is the difference between a partial agonist and an antagonist?

An antagonist binds the receptor without activating it. A partial agonist binds and produces a measurable but submaximal response. In the presence of a full agonist, a partial agonist can behave as a functional antagonist by competing for binding and limiting the overall response.

Is 7-OH a partial agonist?

Yes, in published in vitro research. 7-Hydroxymitragynine is characterized as a partial agonist at the mu-opioid receptor with G-protein-biased signaling.

What is buprenorphine and why is it relevant?

Buprenorphine is the canonical clinical example of a mu-opioid receptor partial agonist. Its clinical use in opioid dependence treatment is grounded in its dual behavior - activating MOR in the absence of a full agonist and competing with full agonists in their presence.

Receptor Pharmacology

Partial Agonist

At-a-glance comparison

Spec	Value
Definition	A receptor ligand that produces a submaximal Emax even at saturating concentration
Maximum response (Emax)	Always less than 100% relative to a full agonist
Behavior in absence of full agonist	Activates the receptor, producing a response
Behavior in presence of full agonist	Can compete for binding and reduce the full agonist's response (functional antagonism)
Reference MOR partial agonists	Buprenorphine; oliceridine (also G-protein biased); 7-OH; mitragynine; mitragynine pseudoindoxyl
Quantification framework	Operational efficacy (τ); intrinsic efficacy

What is a partial agonist?

Receptor ligands are categorized by what they do to the receptor when they bind. Agonists activate the receptor, antagonists block activation, and inverse agonists actively suppress baseline receptor activity. Within the agonist category, ligands are further distinguished by the maximum functional response they can produce - their Emax in pharmacology shorthand.

A full agonist produces 100% of the maximum functional response the receptor system is capable of (relative to a defined reference). A partial agonist produces a submaximal Emax - for example, 50% of the full-agonist response - even at concentrations high enough to occupy every receptor. Increasing the dose of a partial agonist beyond receptor saturation does not push the response higher. The submaximal ceiling is a property of the ligand itself, not of how much of it is administered.

What partial agonism implies pharmacologically

Two consequences follow from partial agonism. First, in the absence of a full agonist, a partial agonist activates the receptor and produces a measurable functional response. Second, in the presence of a full agonist, a partial agonist competes with the full agonist for receptor occupancy and - because it generates a smaller maximum response - reduces the overall functional output. In this latter scenario, a partial agonist behaves as a functional antagonist of the full agonist. Buprenorphine's clinical use in opioid dependence treatment is grounded in exactly this dual property at the mu-opioid receptor.

Partial agonism is one parameter of receptor-ligand interaction; biased agonism (which downstream pathway is preferentially activated) and binding affinity (how tightly the ligand binds) are independent parameters. A ligand can be both partial and biased - 7-OH is one example - and this combination is part of why kratom alkaloid pharmacology has attracted research attention.

Partial agonism in kratom alkaloid pharmacology

In published in vitro work, mitragynine acts as a partial agonist at the mu-opioid receptor with weaker binding affinity than morphine. 7-Hydroxymitragynine is also a partial MOR agonist, with substantially higher binding affinity than mitragynine and a similarly G-protein-biased signaling profile. Mitragynine pseudoindoxyl, a rearrangement product of 7-OH, is also a partial MOR agonist in published research and shows the highest binding affinity of the three.

These pharmacology findings come from cell-based and biochemical assays performed in academic and industry laboratories. They describe receptor-level interactions in research models only and should not be interpreted as evidence of safety, efficacy, or any clinical or therapeutic effect in humans.

Common questions about partial agonist

What is a partial agonist in simple terms?: A receptor ligand that can only push the receptor part of the way to its maximum response, even at very high doses. The ceiling on its response is a property of the ligand itself.
What is the difference between a partial agonist and a full agonist?: A full agonist can produce the maximum functional response the receptor system is capable of (Emax = 100% relative to reference). A partial agonist produces a submaximal Emax even at saturating concentration.
What is the difference between a partial agonist and an antagonist?: An antagonist binds the receptor without activating it. A partial agonist binds and produces a measurable but submaximal response. In the presence of a full agonist, a partial agonist can behave as a functional antagonist by competing for binding and limiting the overall response.
Is 7-OH a partial agonist?: Yes, in published in vitro research. 7-Hydroxymitragynine is characterized as a partial agonist at the mu-opioid receptor with G-protein-biased signaling.
Is mitragynine a partial agonist?: Yes. Mitragynine is a partial agonist at the mu-opioid receptor with weaker binding affinity than 7-OH and a similarly G-protein-biased profile.
What is buprenorphine and why is it relevant?: Buprenorphine is the canonical clinical example of a mu-opioid receptor partial agonist. Its clinical use in opioid dependence treatment is grounded in its dual behavior - activating MOR in the absence of a full agonist and competing with full agonists in their presence.

References

Kenakin T. (2019). Biased receptor signaling in drug discovery. Pharmacological Reviews.
Váradi A, Marrone GF, Palmer TC, et al. (2016). Mitragynine/Corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism. J Med Chem. PMID 27513560.
Kruegel AC, Gassaway MM, Kapoor A, et al. (2016). Synthetic and receptor signaling explorations of the Mitragyna alkaloids. JACS.
Walsh SL, Eissenberg T. (2003). The clinical pharmacology of buprenorphine. Drug and Alcohol Dependence.

Important safety information:

Products containing 7-hydroxymitragynine (7-OH) are sold for adult use only (21+). These statements have not been evaluated by the U.S. Food and Drug Administration. Products are not intended to diagnose, treat, cure, or prevent any disease. The FDA has raised safety concerns regarding concentrated 7-OH products; consult a qualified healthcare professional before use. Do not operate vehicles or machinery after use. Keep out of reach of children and pets. Laws vary by state, buyers are responsible for knowing applicable law.